University of Utah John A. Moran Eye Center
Welcome,         Profile    Billing    Logout  
 4 Trials 
9 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bernstein, Paul S
NCT03316300 / 2017-003234-82: A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A

Completed
3
120
Europe, US, RoW
NT-501, Sham Procedure
Neurotech Pharmaceuticals, The Lowy Medical Research Institute Limited
Macular Telangiectasia Type 2 (MacTel)
08/22
09/22
NAC Attack, NCT05537220: Oral N-acetylcysteine for Retinitis Pigmentosa

Recruiting
3
438
Europe, Canada, US, RoW
N-acetylcysteine, Placebo
Johns Hopkins University, National Eye Institute (NEI), Duke University, Emory University, Massachusetts Eye and Ear Infirmary, Mayo Clinic, Medical College of Wisconsin, Retina Foundation of the Southwest, Stanford University, University of California, Davis, University of Florida, University of Iowa, University of Miami, University of Michigan, University of Minnesota, University of Oklahoma, University of Southern California, University of Utah, University of Washington, University of Wisconsin, Madison, Vanderbilt University, Vitreo Retinal Associates, PA, University of Houston, Medical University of Graz, McGill University, Universität Tübingen, Centro Medico ABC, Radboud University Medical Center, University of Amsterdam, University Hospital, Basel, Switzerland, University College London Hospitals, Northwestern University, University of Pennsylvania
Retinitis Pigmentosa
12/28
12/28
SAFE Study, NCT04907084: Serine and Fenofibrate Study in Patients With MacTel Type 2

Active, not recruiting
2
60
Europe, US
Serine, Fenofibrate
The Lowy Medical Research Institute Limited
Macular Telangiectasia Type 2
03/24
03/24
MAGENTA, NCT05265624: The Moran AMD Genetic Testing Assessment Study

Completed
2
76
US
Early disclosure of genetic testing results, Late disclosure of genetic testing results
Paul S. Bernstein
Age-Related Macular Degeneration, Genetic Testing, Nutritional Biomarkers
07/24
07/24
NCT03022773: Macular Pigment Measurements in Eye & Other Tissues

Recruiting
N/A
10000
US
Carotenoid measurements
University of Utah
Macular Pigmentation, Skin Pigment
06/25
06/25
Uni-Rare, NCT05589714: Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants

Recruiting
N/A
1500
Europe, Canada, US, RoW
Jaeb Center for Health Research, Foundation Fighting Blindness
Inherited Retinal Degeneration, Retinitis Pigmentosa
12/28
12/28
Katz, Bradley J
THRIVE, NCT05176639 / 2021-006794-37: A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants with Thyroid Eye Disease (TED) ( )

Active, not recruiting
3
154
Europe, Canada, US, RoW
Veligrotug (VRDN-001) Phase 1/2 MAD (HV and TED), VRDN-001 Phase 3 Cohort (THRIVE), VRDN-001 Placebo
Viridian Therapeutics, Inc., Viridian Therapeutics, Inc.
Thyroid Eye Disease
07/24
03/25
NARROW, NCT05305079: NA-AION Risk Factors: New Perspectives

Completed
N/A
179
Europe, Canada, US, RoW
Rigshospitalet, Denmark, Velux Fonden, Fight for Sight, University of Copenhagen, Hamilton Health Sciences Corporation, Aarhus University Hospital, Aalborg University Hospital, Odense University Hospital, Farabi Eye Hospital, Wellington Hospital, University of Colorado, Denver, University of Utah, Lawson Health Research Institute, University of Sydney, Stanford University, Moorfields Eye Hospital NHS Foundation Trust, Massachusetts Eye and Ear Infirmary, University Hospital, Bordeaux, Synoptik-Fonden
Non-arteritic Ischemic Optic Neuropathy, Optic Disk Drusen
08/24
08/24
Lucci, Lucia
MAGENTA, NCT05265624: The Moran AMD Genetic Testing Assessment Study

Completed
2
76
US
Early disclosure of genetic testing results, Late disclosure of genetic testing results
Paul S. Bernstein
Age-Related Macular Degeneration, Genetic Testing, Nutritional Biomarkers
07/24
07/24

Download Options